Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with revenue and EPS growth, alongside strategic developments like the Pfizer partnership and biosimilar expansion. The Q&A section reveals management's confidence in future growth, despite some uncertainties in the government channel and lack of specific guidance for 2026. The market cap suggests moderate sensitivity to these factors, leading to a positive stock price outlook.
Key Financial Performance
Revenue Growth 2025 revenue grew 8% year-over-year. This growth was driven by portfolio expansion and strong performance across all business segments.
Adjusted EBITDA Adjusted EBITDA increased 10% year-over-year in 2025, reflecting top-line growth and limited operating expense growth.
Adjusted EPS Adjusted EPS rose 43% year-over-year in 2025, driven by adjusted EBITDA growth and lower interest expense due to favorable refinancing.
Q4 Revenue Q4 2025 revenues grew 11% year-over-year to $814 million, driven by strong demand across key brands and new product launches.
Q4 Adjusted EBITDA Q4 2025 adjusted EBITDA grew 13% year-over-year to $175 million, supported by revenue growth and limited operating expense growth.
Q4 Adjusted EPS Q4 2025 adjusted EPS grew 75% year-over-year to $0.21, driven by adjusted EBITDA growth and lower interest expense.
Operating Cash Flow Full-year 2025 operating cash flow was $340 million, reflecting strong financial performance and operational efficiency.
Net Leverage Net leverage reduced to 3.5x by the end of 2025, down from 3.9x in 2024, due to strong cash flow and refinancing efforts.
Adjusted Gross Margin 2025 adjusted gross margin expanded by 50 basis points to approximately 43%, driven by a mix shift towards higher-margin products.
Health Care Segment Revenue Health Care segment revenue grew 12% year-over-year in 2025, driven by strong growth in the government channel.
Specialty Segment Revenue Specialty segment revenue grew 19% year-over-year in 2025, supported by strong demand for key brands like CREXONT and RYTARY.
Affordable Medicines Segment Revenue Affordable Medicines segment revenue grew 4% year-over-year in 2025, reflecting the timing of key product launches and approvals.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CREXONT: Achieved 3% market share one year post-launch with 23,000 patients on therapy. Interim Phase IV data shows it delivers more "Good On" time for Parkinson's patients. Expected peak U.S. sales of $300M-$500M.
Brekiya: Launched as the first auto-injector for severe migraine and cluster headache patients. Expected peak sales of $50M-$100M.
Affordable Medicines: Launched 20-30 new products annually, focusing on complex generics, injectables, and inhalation products. Expanded portfolio with late 2025 approvals including risperidone extended-release and sodium oxybate.
Injectables: Aiming to become a top 5 player in the U.S. institutional market. Expanded R&D and manufacturing capabilities with over 40 products and a pipeline of differentiated launches.
Biosimilars: Received approval for denosumab biosimilars and expects to have 6 biosimilars in the U.S. market by 2027. Targeting vertical integration for long-term success.
GLP-1 Collaboration: Collaboration with Pfizer progressing well. Building two new facilities for large-scale peptide production and advanced sterile fill-finish manufacturing.
Operational Efficiencies: Enhanced efficiency through digitization, automation, and AI. Reduced net leverage to 3.5x and refinanced debt to lower interest costs.
Manufacturing: Building scalable and flexible manufacturing platforms for GLP-1s and other complex medicines.
Strategic Growth: Focused on becoming America's #1 affordable medicines company. Diversified portfolio across affordable medicines, specialty, and biosimilars.
Specialty Expansion: Plans to expand specialty portfolio in CNS and other areas with differentiated delivery and patient convenience.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals and Launches: The company's growth heavily depends on regulatory approvals and successful launches of new products. Any delays or failures in obtaining these approvals could adversely impact revenue growth.
Specialty Segment Growth: The Specialty segment's growth is expected to pause temporarily in 2026 due to generic erosion of RYTARY, which could impact overall revenue and profitability.
Biosimilar Market Competition: The biosimilar market is highly competitive, and the company's success depends on being among the first to market with new biosimilars. Failure to achieve this could limit market share and revenue potential.
Manufacturing and Supply Chain: The company is expanding its manufacturing capabilities, including two new GLP-1 facilities. Any delays or inefficiencies in these expansions could disrupt supply and impact financial performance.
Economic and Market Conditions: Economic uncertainties and market conditions could affect the demand for the company's products, particularly in the Affordable Medicines segment.
Debt and Financial Leverage: Although the company has reduced its net leverage, it still carries significant debt. Any adverse changes in interest rates or financial performance could strain its financial position.
Healthcare Segment Revenue Decline: The Healthcare segment is expected to see a revenue decline in 2026, which could impact overall financial performance despite efforts to maintain profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Affordable Medicines Segment: Meaningful acceleration in revenue growth expected in 2026 and 2027, driven by an expanding portfolio of complex differentiated and durable products. Plans to launch 20 to 30 new products each year, focusing on high-value and complex generics.
Injectables: Ambition to become a top 5 player in the U.S. institutional market. Substantial scaling expected over time with over 40 products and a pipeline of differentiated launches.
Biosimilars: Goal to have 6 biosimilars in the U.S. market by 2027. Significant long-term growth opportunity due to upcoming biologics losing exclusivity. Plans for vertical integration across development, manufacturing, and commercialization.
GLP-1 Collaboration with Pfizer: Progressing well with manufacturing build-out of two new facilities for large-scale peptide production and advanced sterile fill-finish manufacturing. Positioned for meaningful long-term participation in the GLP-1 market.
Specialty Segment: Peak U.S. sales of $300 million to $500 million expected for CREXONT. Brekiya auto-injector projected to achieve peak sales of $50 million to $100 million. Specialty business expected to resume strong growth trajectory in 2027 and beyond.
2026 Financial Guidance: Revenue growth projected between 1% and 4%, adjusted EBITDA growth between 5% and 10%, and adjusted EPS growth between 12% and 24%. Adjusted gross margins expected to exceed 44%, with operating cash flow between $325 million and $375 million.
Health Care Segment: Revenue expected between $625 million to $700 million in 2026, with flat profitability year-over-year. Long-term growth potential driven by expanding government and distribution channels and new product launches.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the market response to CREXONT's Phase IV data and provide revenue or market share targets for 2026?
A:The Phase IV interim results show 3.13 hours of 'Good On' time, with 80% of IR patients converting to CREXONT. The company aims to double market share and more than double revenue by 2026, targeting 100,000 patients initially and 200,000 patients later out of a total 700,000 CD-LD treatment patients.
Q:What growth is expected in the higher-margin government channel versus the distribution business for 2026, and what are the gross margin expectations?
A:The distribution business is expected to decline, while the government business will also see a slight decline due to increased competition for generic Entresto. Despite this, gross margins are expected to remain stable due to resource allocation to more profitable areas and cost management. In 2025, gross margin grew by 41% and operating income by 65% compared to 2024.
Q:What is the latest update on the Pfizer GLP-1 obesity partnership and potential outcomes?
A:The partnership with Pfizer is progressing well, with manufacturing facilities accelerating and Phase III trials awaited. The company retains marketing rights for 18 countries, including India and Southeast Asia. There are no current plans for a buyout or changes in the partnership.
Q:What are the company's business development strategies, areas of interest, and plans for vertical integration of biosimilars?
A:The company is focusing on vertical integration of biosimilars, leveraging streamlined regulations and market familiarity. Capital allocation will prioritize biosimilars, with a focus on specialty assets and pipeline development from 2027 onward. The company also continues to invest in R&D and CapEx for complex products.
Q:What are the expectations for the generic Omnipaque (Iohexol) and Xolair opportunities?
A:For Iohexol, the company expects a ramp-up due to supply chain complexities, with meaningful revenue contribution starting in 2027. All strengths are expected to be approved by the end of the year. For Xolair, the company anticipates significant market penetration through private label partnerships, with 65-70% of sales expected through this channel, enabling immediate market share gains.
Q:Can you quantify CREXONT's persistence and gross-to-net expectations, and provide details on the DHE auto-injector's early patient profile?
A:CREXONT is outperforming RYTARY, with 23,000 patients and a 3% market share in its first year. Gross-to-net is around 40-45%. The DHE auto-injector targets both cluster headaches and severe migraines, with a focus on key migraine treatment centers and KOLs. Early feedback has been very positive.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the potential outcomes of the Pfizer GLP-1 obesity partnership, particularly regarding scenarios like a complete buyout or the future of new facilities in India. They also did not provide specific gross margin figures for 2026, instead offering general trends and qualitative insights.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brekiya auto
CD LD
CREXONT
Chintu
Health Care
Health care
IR CD
RYTARY
Xolair
acceleration
approval launch
auto injector
build
capability term
care Specialty
care margin
consistency
control
decade
delivery
detail
effort
engine
excellence portfolio
inhalation
launch biosimilars
manufacturing capability
maturity interest
medicine launch
path
platform
product approval
specialty product
standard care
system
top line
wave
AMRX Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call highlights strong financial performance with revenue and EPS growth, alongside strategic developments like the Pfizer partnership and biosimilar expansion. The Q&A section reveals management's confidence in future growth, despite some uncertainties in the government channel and lack of specific guidance for 2026. The market cap suggests moderate sensitivity to these factors, leading to a positive stock price outlook.
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
AMRX Slides
AMRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
